Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals CFO Erick Frim resigns; Eric Sherb named CFO effective Oct. 1

Neutral Impact 3 of 5 leadership Written later

Apimeds Pharmaceuticals US, Inc. said interim Chief Financial Officer Erick Frim resigned effective immediately on September 29, 2026, with the company stating the resignation was not due to any disagreement on operations, policies or practices. The Board appointed Eric Sherb, a Certified Public Accountant, as Chief Financial Officer effective October 1, 2026, at a base salary of $60,000 per year. The change in the company's principal financial officer role is a leadership transition that shareholders may track.

Key points

  • Erick Frim resigned as interim CFO effective immediately; notice given September 29, 2026
  • Eric Sherb, age 40, appointed CFO by the Board on September 30, 2026, effective October 1, 2026
  • Sherb's base salary is $60,000 per year under an Executive Employment Agreement; equity awards may be granted in the future
  • Sherb's fractional CFO engagement at subsidiary MindWave Innovations Inc. will terminate in connection with his appointment

The filing

CompanyApimeds Pharmaceuticals US, Inc. (APUS)
Form8-K, current report
Filed with the SECOct 1, 2026, 9:15 AM ET
Accession number0001213900-26-105484

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.